HLA-haploidentical bone marrow transplantation for severe combined immunodeficiency using E rosette fractionation and cyclosporine.

Eight patients with severe combined immunodeficiency received bone marrow cells from their HLA haplotype-identical fathers after bone marrow T cell depletion by rosetting with neuraminidase-treated sheep red cells. Because the method led to the infusion of a small percentage of T lymphocytes (0.1% to 0.3%), cyclosporin was given by continuous intravenous infusion for two months in order to prevent the occurrence of graft-v-host disease (GVHD). Three patients who did have residual nonfunctional T lymphocytes received busulfan and cyclophosphamide before transplantation. Engraftment was observed in seven patients, and severe GVHD was not seen. Two patients died early after the bone marrow transplantation because of prior infections, and a third died at day 90 from a B cell lymphoproliferative syndrome. The five other patients are doing well. Stable engraftment has been achieved with reconstitution of cell-mediated immunity in 5/5 and humoral immunity in 4/5 patients.

[1]  R. Dinsmore,et al.  Marrow transplantation for congenital disorders. , 1984, Seminars in hematology.

[2]  W. Friedrich,et al.  IMMUNORECONSTITUTION IN SEVERE COMBINED IMMUNODEFICIENCY AFTER TRANSPLANTATION OF HLA-HAPLOIDENTICAL, T-CELL-DEPLETED BONE MARROW , 1984, The Lancet.

[3]  T. Beveridge,et al.  LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN THERAPY , 1984, The Lancet.

[4]  R. Good,et al.  Bone marrow transplantation--an expanding approach to treatment of many diseases. , 1983, Cellular immunology.

[5]  F. Rosen,et al.  Application of bone marrow transplantation in genetic diseases. , 1983, Clinics in haematology.

[6]  A. Gratwohl,et al.  IMMUNOLOGIC REACTIVITY IN MARROW GRAFT RECIPIENTS RECEIVING CYCLOSPORINE TO PREVENT GRAFT‐VERSUS‐HOST DISEASE , 1983, Transplantation.

[7]  B. Dupont,et al.  Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. , 1983, Blood.

[8]  B. Dupont,et al.  Transplantation of hematopoietic cells for lethal congenital immunodeficiencies. , 1983, Birth defects original article series.

[9]  R. Levinsky,et al.  Problems of mismatched bone marrow transplantation for severe combined immunodeficiency after soybean lectin fractionation. , 1983, Birth defects original article series.

[10]  S. Murphy,et al.  Failure of a pan-reactive anti-T cell antibody, OKT 3, to prevent graft versus host disease in severe combined immunodeficiency. , 1982, The Journal of pediatrics.

[11]  A. Hess,et al.  Effect of cyclosporin A on human lymphocyte responses in vitro. IV. Production of T cell stimulatory growth factors and development of responsiveness to these growth factors in CsA-treated primary MLR cultures. , 1982, Journal of immunology.

[12]  J. Sloane,et al.  CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION , 1980, The Lancet.

[13]  J. Kersey,et al.  Lymphoma after thymus transplantation. , 1980, The New England journal of medicine.

[14]  C. Griscelli,et al.  Selective defect of precursor T cells associated with apparently normal B lymphocytes in severe combined immunodeficiency disease. , 1978, The Journal of pediatrics.

[15]  J. Sprent,et al.  Tolerance to histocompatibility determinants in tetraparental bone marrow chimeras , 1975, The Journal of experimental medicine.

[16]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[17]  R. Gatti,et al.  Immunological reconstitution of sex-linked lymphopenic immunological deficiency. , 1968, Lancet.